Table 1.

Clinical status of the mAb pipeline for HIV prevention trials

Antibody	Target	Clinical trial completed	Ongoing/in development
VRC01	CD4bs	NCT02568215, NCT02716675, NCT02797171, NCT03831945, NCT02579083, NCT02165267, NCT01993706, NCT01950325, NCT02471326, NCT02664415, NCT02411539, NCT03208231, NCT02463227	NCT02256631, NCT02140255, NCT04860323, NCT04801758, NCT02591420
VRC01‐LS	CD4bs	NCT02797171, NCT02599896, NCT02840474	NCT03707977, NCT02256631
VRC07‐523‐LS	CD4bs	NCT02840474, NCT03205917, NCT03015181, NCT03387150, NCT03565315 (term), NCT03735849,	NCT03928821, NCT04212091, NCT02256631, NCT04357821, NCT04340596, NCT03739996, NCT03721510, NCT03803605
3BNC117 and 3BNC117‐LS	CD4bs	NCT02825797, NCT02824536, NCT03571204, NCT02018510, NCT02850016, NCT03254277, NCT02588586, NCT02446847	NCT04811040, NCT04319367, NCT04720742 (susp), NCT03837756, NCT04173819, NCT03588715, NCT03554408, NCT03526848, NCT04250636, NCT03041012, NCT04819347, NCT04560569
CAP256V2LS	V2‐apex		NCT04408963
PGDM1400 and PGDM1400‐LS	V2‐apex	NCT03205917	NCT03928821, NCT03721510
PGT121 and PGT121‐LS and PGT121.414.LS	V3‐glycan	NCT03205917, NCT02960581	(NCT03928821, NCT03721510, NCT04212091
10‐1074 and 10‐1074‐LS	V3‐glycan	NCT02825797, NCT02511990, NCT02824536, NCT03831945, NCT03571204	NCT03928821, NCT03707977, NCT04340596, NCT04811040, NCT04357821, NCT04319367, NCT04720742 (susp), NCT03837756, NCT03619278, NCT04173819, NCT03588715, NCT03554408, NCT03526848, NCT04250636
SAR441236 (Sanofi trispecific)	CD4bs, V2‐apex, MPER		NCT03705169)
iMAb/10E8v4	MPER		NCT03875209
10E8‐LS	MPER	NCT03565315 (term)

Note: Trials registered at clinicaltrials.gov. Includes trials in healthy adults, people living with HIV, and HIV‐exposed infants.

Studies considered completed based on clinicaltrials.gov.

Abbreviations: Susp, suspended; Term, terminated.